scholarly journals A Real-World Observational Study of Patients with Advanced Melanoma Receiving First-Line Ipilimumab in a Community Practice Setting

2014 ◽  
Vol 05 (12) ◽  
pp. 1049-1058 ◽  
Author(s):  
Debra A. Patt ◽  
Debra Rembert ◽  
Menaka Bhor ◽  
Debajyoti Bhowmik ◽  
Sumati A. Rao
Keyword(s):  
Observational Study ◽  
Real World ◽  
Advanced Melanoma ◽  
Practice Setting ◽  
Community Practice ◽  
First Line

scholarly journals Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study

2020 ◽  
Vol 43 (8) ◽  
pp. 256-264
Author(s):  
Michiel C.T. van Zeijl ◽  
John B.A.G. Haanen ◽  
Michel W.J.M. Wouters ◽  
Liesbeth C. de Wreede ◽  
Anouk Jochems ◽  
...  
Keyword(s):  
Real World ◽  
Population Based ◽  
Advanced Melanoma ◽  
First Line ◽  
Population Based Study

Efficacy of pertuzumab in combination with trastuzumab and a taxane in first-line treatment for metastatic breast cancer (MBC): A multicenter, retrospective, observational study.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12504-e12504 ◽  
Author(s):  
Teresa Gamucci ◽  
Lucia Mentuccia ◽  
Isabella Sperduti ◽  
Alain Gelibter ◽  
Loretta D'Onofrio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Observational Study ◽  
Real World ◽  
Metastatic Breast ◽  
Progression Free Survival ◽  
Rank Test ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

e12504 Background: Pertuzumab (P) , Trastuzumab (T) and Docetaxel (D) is standard first-line treatment in patients (pts) with HER2 + metastatic breast cancer (MBC). This multicenter retrospetive observational study was performed to evaluate the activity of P and T in combination with D or Paclitaxel (Tx) in real world HER2 + MBC pts. Methods: We identified HER2 + MBC pts treated with P, T and D or Ptx optionally followed by P, T and endocrine therapy (ET) maintenance in hormone positive (HR+) BC, in 17 Italian cancer centres between 09/2012 and 08/2016. Overall Survival (OS) and Progression Free Survival (PFS) were calculated by the Kaplan-Meier product-limit method. Log-rank test was used to assess differences between subgroups. Results: 191 pts were included in our analysis. Pts characteristics: median age 54 years (range 29-80); PS 0 in 127 (67%) pts and PS 1 in 54 (28%); 107 (56%) had visceral metastases (mts), 23 (12%) only bone mts and 28 (15%) brain mts, 130 (68%) were ER/PgR +. 76 pts (40%) were metastatic at diagnosis; 148 (78) were treated with D while 43 (22%) with Tx. The ORR was 78% (CI 95% 72-84), RC 18% and RP 60%, only 10 (5%) had PD. To date, of the 54 pts treated with ET maintenance, 26% had a further improvement of response (7 pts had RC). At median follow-up of 17 months (mo) (range 6- 52), median PFS was 20 mo (95% CI 14-26) and median OS at 2 years was 80%. No differences in PFS were found for age (p = 0.92), PS (p = 0.18), receptor status (p = 0.57), visceral mts (p = 0.54) and chemotherapy (cht) type (p = 0.47), whereas number of mts site (1 vs > 1) affected PFS (28 vs 16 mo, p = 0.002). Moreover median PFS in naïve pts and in pts pretreated with only cht was 28 mo (95% CI, 20-36) and 27 mo (95% CI, 16-38) respectively, whereas in pts pretreated with T it was 12 mo (95% CI 16-38 p 0.002). In HR+ pts ET maintenance together with P and T had an impact on PFS (28 vs 15 mo, p = 0.01). Conclusions: Our analysis confirms, in real world HER2 MBC pts, the efficacy of P, T and a taxane combination in first line treatment; in this population PFS was shorter in pts pretreated with T. ET maintenance in association with P and T in HR+ pts improved PFS. Data collection is ongoing and update results will be presented.

scholarly journals Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Gwo-Fuang Ho ◽  
Chee-Shee Chai ◽  
Adlinda Alip ◽  
Mohd Ibrahim A. Wahid ◽  
Matin Mellor Abdullah ◽  
...  
Keyword(s):  
Side Effects ◽  
Observational Study ◽  
Brain Metastases ◽  
Real World ◽  
Advanced Nsclc ◽  
Response Rate ◽  
Group Performance ◽  
Resistance Mechanisms ◽  
First Line ◽  
Multicenter Observational Study

Abstract Background This study aimed to evaluate the efficacy, side-effects and resistance mechanisms of first-line afatinib in a real-world setting. Methods This is a multicenter observational study of first-line afatinib in Malaysian patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC). Patients’ demographic, clinical and treatment data, as well as resistance mechanisms to afatinib were retrospectively captured. The statistical methods included Chi-squared test and independent t-test for variables, Kaplan-Meier curve and log-rank test for survival, and Cox regression model for multivariate analysis. Results Eighty-five patients on first-line afatinib from 1st October 2014 to 30th April 2018 were eligible for the study. EGFR mutations detected in tumors included exon 19 deletion in 80.0%, exon 21 L858R point mutation in 12.9%, and rare or complex EGFR mutations in 7.1% of patients. Among these patients, 18.8% had Eastern Cooperative Oncology Group performance status of 2–4, 29.4% had symptomatic brain metastases and 17.6% had abnormal organ function. Afatinib 40 mg or 30 mg once daily were the most common starting and maintenance doses. Only one-tenth of patients experienced severe side-effects with none having grade 4 toxicities. The objective response rate was 76.5% while the disease control rate was 95.3%. At the time of analysis, 56 (65.9%) patients had progression of disease (PD) with a median progression-free survival (mPFS) of 14.2 months (95% CI, 11.85–16.55 months). Only 12.5% of the progressed patients developed new symptomatic brain metastases. The overall survival (OS) data was not mature. Thirty-three (38.8%) patients had died with a median OS of 28.9 months (95% CI, 19.82–37.99 months). The median follow-up period for the survivors was 20.0 months (95% CI, 17.49–22.51 months). Of patients with PD while on afatinib, 55.3% were investigated for resistance mechanisms with exon 20 T790 M mutation detected in 42.0% of them. Conclusions Afatinib is an effective first-line treatment for patients with EGFR-mutant advanced NSCLC with a good response rate and long survival, even in patients with unfavorable clinical characteristics. The side-effects of afatinib were manageable and T790 M mutation was the most common resistance mechanism causing treatment failure.

scholarly journals First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis

2020 ◽  
Author(s):  
Anna C Pavlick ◽  
Ruizhi Zhao ◽  
Cho-Han Lee ◽  
Corey Ritchings ◽  
Sumati Rao
Keyword(s):  
Real World ◽  
Advanced Melanoma ◽  
First Line ◽  
Risk Of Death ◽  
Real World Setting ◽  
Significant Survival ◽  
Baseline Characteristics ◽  
Braf Mutant ◽  
Electronic Medical Record Database

Aim: To compare effectiveness of nivolumab + ipilimumab (NIVO + IPI) versus BRAF + MEK inhibitors (BRAFi + MEKi) in patients with BRAF-mutant advanced melanoma in the real-world setting. Materials & methods: This study used the Flatiron Health electronic medical record database. Results: After adjusting for differences in baseline characteristics, NIVO + IPI was associated with a 32% reduction in risk of death versus BRAFi + MEKi. At a mean follow-up of 15–16 months, 64% of NIVO + IPI patients and 43% of BRAFi + MEKi patients were alive; subsequent therapy was administered to 33 and 41% of patients, respectively. After first-line NIVO + IPI, 20% of patients died before subsequent therapy, whereas 32% died after first-line BRAFi + MEKi. Conclusion: In this real-world study, patients treated with first-line NIVO + IPI showed significant survival benefit versus those receiving first-line BRAFi + MEKi.

The patterns of care of follicular lymphoma: First-line treatment in academic and community practice setting.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e19515-e19515
Author(s):  
Philip Schulman ◽  
Elaine Whyler ◽  
Vlad Kozlovsky ◽  
Evan W. Alley ◽  
Paul Gilman ◽  
...  
Keyword(s):  
Follicular Lymphoma ◽  
Patterns Of Care ◽  
Practice Setting ◽  
Community Practice ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

scholarly journals 1056P Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study

2021 ◽  
Vol 32 ◽  
pp. S881-S882
Author(s):  
I. Marquez-Rodas ◽  
M.A. Berciano Guerrero ◽  
E. Muñoz Couselo ◽  
J.L. Manzano ◽  
G. Crespo Herrero ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Real World ◽  
Advanced Melanoma ◽  
Line Treatment ◽  
First Line ◽  
Real World Data ◽  
World Data ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document